NeoGenomics has announced its financial guidance for 2025, projecting total revenues between $735 million and $745 million, marking an anticipated year-over-year growth of 11% to 13% from 2024. This optimistic outlook is driven by the company's strategic focus on product innovation and operational efficiencies, as well as its commitment to expanding its leadership in oncology testing. CEO Chris Smith highlighted the company's patient-centric strategy and the momentum of double-digit revenue growth and margin expansion achieved in recent years. The company also expects adjusted EBITDA to rise significantly, with projections ranging from $55 million to $58 million, reflecting a 43% to 51% increase from the previous year.
The updated Long-Range Financial Plan outlines NeoGenomics' ambition to achieve 12-13% annual revenue growth, with a particular emphasis on next-generation sequencing (NGS) growth of approximately 25% per year. The company also aims for gross margin expansion of 100-150 basis points annually and adjusted EBITDA improvement of 250-300 basis points per year. NeoGenomics plans to serve over 1 million patients annually by 2028, underscoring its commitment to expanding its reach and impact in the oncology diagnostics field.
NeoGenomics (NEO) shares have risen 3.77% to $14.30 as of January 15th, up from the previous close of $13.78.